MBX Biosciences (MBX) Stifel 2024 Healthcare Conference summary

Company overview and platform technology

• Clinical-stage biopharma advancing Precision Endocrine Peptides (PEPs) for optimized drug properties and convenient dosing.

• PEPs leverage proprietary prodrug technology and fatty acylation for extended action and lower variability.

• Raised $400M to date, with $271M in cash, funding operations into mid-2027.

• Pipeline includes programs for hypoparathyroidism, post-bariatric hypoglycemia, and obesity.

• Differentiation centers on infusion-like PK profiles and less frequent injections for improved adherence and outcomes.

Lead program: MBX 2109 for hypoparathyroidism

• MBX 2109 is a long-acting PTH prodrug with once-weekly dosing, aiming to reduce pill burden and excursions in calcium levels.

• Phase II trial (Avail) enrolling, with top-line results expected Q3 2025.

• Orphan drug designation in the US; plans to pursue in EU.

• Device design uses a single-use, pen-like injector for ease of use.

• Market opportunity significant, with 250,000 prevalence in US/EU and potential for market expansion as seen in GLP-1 class.

Competitive landscape and regulatory insights

• Yorvipath, a daily PTH therapy, recently approved but faces device and dosing challenges.

• MBX 2109 aims for less frequent monitoring and improved patient experience.

• Pricing for Yorvipath set at $285,000/year; opportunity exists for once-weekly to capture larger market share.

• MBX 2109's molecular and device differences support regulatory and commercial differentiation.